Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Gross Margin (2016 - 2025)

Haemonetics has reported Gross Margin over the past 17 years, most recently at 59.71% for Q4 2025.

  • For Q4 2025, Gross Margin rose 418.0% year-over-year to 59.71%; the TTM value through Dec 2025 reached 59.35%, up 607.0%, while the annual FY2025 figure was 55.04%, 221.0% up from the prior year.
  • Gross Margin for Q4 2025 was 59.71% at Haemonetics, roughly flat from 59.5% in the prior quarter.
  • Over five years, Gross Margin peaked at 59.82% in Q2 2025 and troughed at 36.35% in Q2 2021.
  • A 5-year average of 53.05% and a median of 53.21% in 2022 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: tumbled -1126bps in 2021 and later skyrocketed 1508bps in 2022.
  • Year by year, Gross Margin stood at 51.08% in 2021, then increased by 2bps to 51.98% in 2022, then increased by 2bps to 52.9% in 2023, then rose by 5bps to 55.53% in 2024, then rose by 8bps to 59.71% in 2025.
  • Business Quant data shows Gross Margin for HAE at 59.71% in Q4 2025, 59.5% in Q3 2025, and 59.82% in Q2 2025.